

Mo Alavijeh Frsm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3418682/publications.pdf>

Version: 2024-02-01

39
papers

1,230
citations

471509

17
h-index

361022

35
g-index

40
all docs

40
docs citations

40
times ranked

2133
citing authors

#	ARTICLE	IF	CITATIONS
1	Activated Carbon/Pectin Composite Enterosorbent for Human Protection from Intoxication with Xenobiotics Pb(II) and Sodium Diclofenac. <i>Molecules</i> , 2022, 27, 2296.	3.8	9
2	Advances in Genetic Medicine. Highlights from The Society for Medicines Research Online Meeting. Virtual -December 3, 2020. <i>Drugs of the Future</i> , 2021, 46, 243.	0.1	0
3	Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis. <i>Pharmaceutics</i> , 2021, 13, 516.	4.5	11
4	Orally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Rats. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 3174.	2.5	4
5	Multiple Sclerosis: LIFNano-CD4 for Trojan Horse Delivery of the Neuro-Protective Biologic "LIF" Into the Brain: Preclinical Proof of Concept. <i>Frontiers in Medical Technology</i> , 2021, 3, 640569.	2.5	5
6	COVID-19 Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus. <i>Current Pharmaceutical Design</i> , 2021, 27, 1553-1563.	1.9	13
7	Side group ratio as a novel means to tune the hydrolytic degradation of thiolated and disulfide cross-linked polyaspartamides. <i>Polymer Degradation and Stability</i> , 2021, 188, 109577.	5.8	5
8	Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	25
9	The role of mouse tumour models in the discovery and development of anticancer drugs. <i>British Journal of Cancer</i> , 2019, 121, 101-108.	6.4	119
10	Trends in medicinal chemistry. Highlights from the society for medicines research symposium. London, UK - December 6, 2018. <i>Drugs of the Future</i> , 2019, 44, 175.	0.1	0
11	Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2018, 8, 223-228.	3.4	37
12	Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	23
13	Preparation of liposomes containing small gold nanoparticles using electrostatic interactions. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 105, 55-63.	4.0	29
14	Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 203-209.	2.5	11
15	DNA Binding and Recognition of a CC Mismatch in a DNA Duplex by Water-Soluble Peptidocalix[4]arenes: Synthesis and Applications. <i>Organic Letters</i> , 2016, 18, 4766-4769.	4.6	10
16	Efficient synthesis of lower rim \pm -hydrazino tetrazolocalix[4]arenes via an Ugi-azide multicomponent reaction. <i>New Journal of Chemistry</i> , 2015, 39, 6578-6584.	2.8	16
17	Influence of different types of carbon nanotubes on muscle cell response. <i>Materials Science and Engineering C</i> , 2015, 46, 218-225.	7.3	16
18	Bioabsorbable Stent Quo Vadis: A Case for Nano-Theranostics. <i>Theranostics</i> , 2014, 4, 514-533.	10.0	11

#	ARTICLE	IF	CITATIONS
19	Comparative in vitro stability and scintigraphic imaging for trafficking and tumor targeting of a directly and a novel ^{99m} Tc(I)(CO) ₃ labeled liposome. <i>International Journal of Pharmaceutics</i> , 2014, 465, 333-346.	5.2	12
20	Surface modification of a polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating for enhanced capture of endothelial progenitor cells. <i>Biointerphases</i> , 2013, 8, 23.	1.6	39
21	Inception to actualization: Next generation coronary stent coatings incorporating nanotechnology. <i>Journal of Biotechnology</i> , 2013, 164, 151-170.	3.8	60
22	Nanotechnology-Based Gene-Eluting Stents. <i>Molecular Pharmaceutics</i> , 2013, 10, 1279-1298.	4.6	19
23	Overview of Experimental Models of the Blood-Brain Barrier in CNS Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2013, 62, 7.15.1-7.15.30.	4.0	17
24	An Anti-CD34 Antibody-Functionalized Clinical-Grade POSS-PCU Nanocomposite Polymer for Cardiovascular Stent Coating Applications: A Preliminary Assessment of Endothelial Progenitor Cell Capture and Hemocompatibility. <i>PLoS ONE</i> , 2013, 8, e77112.	2.5	41
25	Kinases: new horizons. Highlights from the Society of Medicines Research Symposium, held on October 3rd, 2013 - National Heart and Lung Institute, Kensington, London, UK. <i>Drugs of the Future</i> , 2013, 38, 789.	0.1	0
26	Translational CNS medicines research. <i>Drug Discovery Today</i> , 2012, 17, 1068-1078.	6.4	47
27	Next generation stent coatings: convergence of biotechnology and nanotechnology. <i>Trends in Biotechnology</i> , 2012, 30, 406-409.	9.3	25
28	The importance of (Bio)pharmaceutical properties in successful drug design: Highlights from the Society of Medicines Research Symposium, held on October 4th, 2012 - National Heart and Lung Institute, Kensington, London. <i>Drugs of the Future</i> , 2012, 37, 879.	0.1	1
29	Nerve regeneration with aid of nanotechnology and cellular engineering. <i>Biotechnology and Applied Biochemistry</i> , 2011, 58, 288-300.	3.1	31
30	Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds. <i>Neurobiology of Disease</i> , 2010, 37, 38-47.	4.4	35
31	Neurochemical changes in a double transgenic mouse model of Alzheimer's disease fed a pro-oxidant diet. <i>Neurochemistry International</i> , 2010, 57, 504-511.	3.8	8
32	Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. <i>NeuroRx</i> , 2005, 2, 554-571.	6.0	380
33	The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. <i>IDrugs: the Investigational Drugs Journal</i> , 2004, 7, 755-63.	0.7	11
34	Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. <i>British Journal of Pharmacology</i> , 2000, 130, 242-248.	5.4	61
35	Microdialysis Study of the Neuropharmacokinetics of Phenytoin in Rat Hippocampus and Frontal Cortex. <i>Epilepsia</i> , 1996, 37, 421-427.	5.1	35
36	The use of microdialysis for the study of drug kinetics: some methodological considerations illustrated with antipyrine in rat frontal cortex. <i>British Journal of Pharmacology</i> , 1995, 115, 503-509.	5.4	17

#	ARTICLE	IF	CITATIONS
37	An evaluation of the epileptogenic properties of a rifampicin/clindamycin-impregnated shunt catheter. <i>British Journal of Neurosurgery</i> , 1994, 8, 725-730.	0.8	14
38	A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): Hematological and biochemical characterization and kinetic evaluation using carbamazepine. <i>Journal of Pharmacological and Toxicological Methods</i> , 1992, 28, 21-28.	0.7	30
39	Effect of denzimol on carbamazepine and carbamazepine-10,11-epoxide concentrations in serum, liver, spleen and different brain regions of the rat: an inhibitory metabolic interaction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1988, 337, 111-4.	3.0	3